We talk with Krzysztof Łanda, founder of the Watch Health Care Foundation, about access to modern methods of treating female cancers and multiple myeloma.
Krzysztof Łanda
Delaying reimbursement decisions for cost-effective therapies is unfair
Published June 23, 2022 14:18
- In the case of advanced endometrial cancer, the prognosis for Polish women is currently not good. The response to treatment with standard chemotherapy is 7-14%.
- Recently, a promising new therapy has emerged, registered under an exceptional regimen, where the response to treatment is around 50% or more.
- Women with endometritis could get reimbursement from the Medical Fund. There is hope for that.
- Multiple myeloma in Poland is treated well, but it is not a treatment with the highest potential potential. Currently, for patients who qualify for high-dose chemotherapy treatment and for transplantation, a drug has appeared, the cost-effectiveness of which is phenomenal.
- In Poland, the statutory profitability threshold is approx. 3 x GDP per capita for 1 QALY, ie one year of life in full health. In many countries the rule is that if treatment falls below 1/3 of the threshold, it is reimbursed automatically.
